R
Ross J. Bland
Researcher at AgResearch
Publications - 27
Citations - 3224
Ross J. Bland is an academic researcher from AgResearch. The author has contributed to research in topics: Teladorsagia circumcincta & Haemonchus contortus. The author has an hindex of 16, co-authored 27 publications receiving 3022 citations. Previous affiliations of Ross J. Bland include Thomas Jefferson University & Columbia University.
Papers
More filters
Journal ArticleDOI
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.
Michael G. Kaplitt,Andrew Feigin,Andrew Feigin,Chengke Tang,Helen L. Fitzsimons,Paul J. Mattis,P. Lawlor,Ross J. Bland,Deborah Young,Kristin Strybing,David Eidelberg,David Eidelberg,Matthew J. During,Matthew J. During +13 more
TL;DR: AAV-GAD gene therapy of the subthalamic nucleus is safe and well tolerated by patients with advanced Parkinson's disease, suggesting that in-vivo gene therapy in the adult brain might be safe for various neurodegenerative diseases.
Journal ArticleDOI
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
Matthew J. During,Lei Cao,David S. Zuzga,Jeremy S. Francis,Helen L. Fitzsimons,Xiangyang Jiao,Ross J. Bland,Matthias Klugmann,William A. Banks,Daniel J. Drucker,Colin N. Haile +10 more
TL;DR: Systemic administration of [Ser(2)]exendin(1–9) in wild-type animals prevents kainate-induced apoptosis of hippocampal neurons and represents a promising new target for both cognitive-enhancing and neuroprotective agents.
Journal ArticleDOI
Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease
Vincent Ries,Claire Henchcliffe,Tatyana Kareva,Margarita Rzhetskaya,Ross J. Bland,Matthew J. During,Nikolai Kholodilov,Robert E. Burke +7 more
TL;DR: Activation of intracellular neurotrophic signaling pathways by vector transfer is a feasible approach to neuroprotection and restorative treatment of neurodegenerative disease.
Journal ArticleDOI
Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.
TL;DR: Glial transduction was observed using rh43 and AAV8, driven by the glial fibrillary acidic protein (GFAP) and myelin basic protein (MBP) promoters, expanding the utility of AAV for modeling and treating diseases involving glial cell pathology.
Journal ArticleDOI
Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy
Francesco Noé,Allan-Hermann Pool,Jari Nissinen,Marco Gobbi,Ross J. Bland,Massimo Rizzi,Claudia Balducci,Francesco Ferraguti,Gunther Sperk,Matthew J. During,Asla Pitkänen,Annamaria Vezzani +11 more
TL;DR: The data show that this gene therapy strategy decreases spontaneous seizures and suppresses their progression in chronic epileptic rats, thus representing a promising new therapeutic strategy.